Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Goldenberries taste like a cross between pineapple and mango, pack the nutritional punch of a superfood, and are increasingly ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 9.03%. Read on to learn why. Crispr Therapeutics AG has seen its stock price rise by 9.03% over ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

Biotech startup CrisprBits uses CRISPR-based techniques to change the shape of diagnostics by decoding genetic sequencing ...

A bespoke CRISPR base-editing therapy designed for a single infant with CPS1 deficiency has produced encouraging early ...

For the scientific enterprise, 2025 was marked by setbacks and challenges. But scientists are no strangers to adversity—the ability to overcome obstacles is built into our training. In turn, research ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Cancer is a leading cause of death worldwide, and among all cancers, colorectal cancer ranks second in mortality, responsible ...

CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development ...